Solasia Pharma Overview
- Founded
-
2006
- Status
-
Public
- Employees
-
78
- Stock Symbol
-
4597
- Share Price
-
$0.36
- (As of Monday Closing)
Solasia Pharma General Information
Description
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors.
Contact Information
Website
www.solasia.co.jp
Formerly Known As
JapanBridge
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
TKS
Primary Office
- 4F Sumitomo Fudosan Shiba-Koen Tower
- 2-11-1 Shiba-koen, Minato-ku
- Tokyo, 105-0011
- Japan
+81 00-0000-0000
Solasia Pharma Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.36 | $0.35 | $0.32 - $0.75 | $59.6M | 168M | 2.04M | -$0.13 |
Solasia Pharma Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 51,412 | 114,236 | 118,141 | 179,374 |
| Revenue | 6,116 | 5,090 | 4,252 | 12,016 |
| EBITDA | (14,442) | (17,521) | (33,901) | (11,805) |
| Net Income | (19,417) | (22,565) | (38,649) | (17,125) |
| Total Assets | 29,634 | 27,322 | 55,996 | 72,968 |
| Total Debt | 353 | 730 | 10,278 | 624 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Solasia Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Solasia Pharma Patents
Solasia Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-WO2019220961-A1 | Crystalline form of darinaparcin alkali metal salt and/or inorganic acid addition salt and preparation thereof | Pending | 18-May-2018 | ||
| JP-2016540775-A | Compounds and methods for the treatment of cancer | Pending | 05-Dec-2013 | 00000000 | 0 |
| US-20160304546-A1 | Compounds and methods for the treatment of cancer | Inactive | 05-Dec-2013 | 00000000 | |
| AU-2009282972-A1 | Organoarsenic compounds and methods for the treatment of cancer | Inactive | 20-Aug-2008 | 0000000000 | |
| ES-2703740-T3 | Organo-arsenic compounds and procedures for the treatment of cancer | Active | 20-Aug-2008 | A61K31/285 |
Solasia Pharma Executive Team (8)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Yoshihiro Arai | President, Representative Director & Board Member | ||
| Toshio Miyashita | Chief Financial Officer, Board Member, Chief Manager & Director | ||
| Vivian Zhang | General Manager | ||
| Koji Shinozaki | Director, Business Development | ||
| Shigeru Sakamaki | Director, Development |
Solasia Pharma Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Dave Preston | Self | Board Member | 000 0000 |
| Norikazu Eiki | Self | Board Member | 000 0000 |
| Stanley Lau | Solasia Pharma | Board Member | 000 0000 |
| Toshio Miyashita | Solasia Pharma | Chief Financial Officer, Board Member, Chief Manager & Director | 000 0000 |
| Yasuhiro Abe | Solasia Pharma | Board Member | 000 0000 |
Solasia Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Solasia Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
